Jun 15, 2023 / 03:00PM GMT
Chris Shibutani - Goldman Sachs Group, Inc., Research Division - Research Analyst
Okay. The green light is on. Welcome, everybody, to the final day of the Goldman Sachs Healthcare Conference. Thank you for all your dedicated stalwart, hard cores. We appreciate the opportunity here to continue here and kick off in our grand ballroom equivalent setting here with Neurocrine.
With us, the Road Warrior CEO, Kevin Gorman; Chief Financial Officer, Matt Abernethy. And together with my colleague, Stephen Sloan, who everybody knows is the only reason that the models all sort of like align. We are very happy to have a discussion here. Lots to talk about in terms of your portfolio, the pipeline, you're also a particularly apt commentator.
And I think that's one of the things that's makes very valuable discussions with you, Kevin and your team, when we think about some of the implications of the broader environment, macro as well as sort of policy changes. So we're going to delve into a bunch of those things.
Neurocrine Biosciences Inc at Goldman Sachs Healthcare Conference Transcript
Feb 08, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers